Back to all studies
RecruitingNCT07185815

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) for Schizophrenia; Bipolarity type I; depression

The registry lists this study as recruiting. Study locations are listed in India and in Israel. Confirm recruitment at each site. It is testing Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) for Schizophrenia; Bipolarity type I; depression.

Depression, Schizophrenia, ...DrugFrom 18 Years to 64 Years
In plain English

Key information made simple

What is this study testing?

This study is testing whether Cariprazine Depot may be useful for adults experiencing depression.

What would participation involve?

Participants may receive Cariprazine Depot, attend study visits with the research team. The registry lists locations in India and in Israel.

Who is it mainly for?

This study appears to be mainly for adults with depression.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: August 1, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
24
Sponsor
Mapi Pharma Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
India, Israel
Age range
From 18 Years to 64 Years
Official registry ID
NCT07185815
Official title
A Prospective, Dose Escalating, Open Label, Multi-center, Phase I/IIa Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine.

Want help reviewing this study?

Loading the security check...
Study ID: NCT07185815. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

India · 2 sites
  • Mapi Pharma Investigational Site IN-101
    Ahmedabad
    Site status: Recruiting
  • Mapi Pharma Investigational Site IN-102
    Ahmedabad
    Site status: Recruiting
Israel · 4 sites
  • Mapi Pharma Investigational Site IL-004
    Beersheba
    Site status: Recruiting
  • Mapi Pharma Investigational Site IL-003
    Ness Ziona
    Site status: Recruiting
  • Mapi Pharma Investigational Site IL-005
    Ramat Gan
    Site status: Recruiting
  • Mapi Pharma Investigational Site IL-001
    Tel Aviv
    Site status: Recruiting
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day. Phase 1 studies usually focus mainly on safety, tolerability, dosage, and side effects. They often involve healthy volunteers, but not always. Some Phase 1 studies include people living with the target condition.

Who might this study be for?

This study may concern people with depression; age range: From 18 Years to 64 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Mapi Pharma Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me